Parkinson's Disease Research Anavex has received a research grant from The Michael J. Fox Foundation to develop ANAVEX®2-73 for Parkinson's disease, focusing on utilizing PET imaging biomarkers to measure target engagement. ANAVEX®3-71 Developments ANAVEX®3-71 is in development for schizophrenia, frontotemporal dementia, and Alzheimer's disease. A Phase 1 trial demonstrated safety and tolerability, and a Phase 2 trial for schizophrenia is underway, showing promising preliminary results. Future Outlook The company plans to advance its clinical programs, focusing on precision medicine approaches and leveraging genomic data to identify biomarkers for better-targeted treatments. The ongoing development of ANAVEX®2-73 and ANAVEX®3-71 is expected to continue, with potential expansion into additional indications. SEC Filing: ANAVEX LIFE SCIENCES CORP. [ AVXL ] - 10-Q - Feb. 12, 2025